Adaptimmune Therapeutics PLC – (ADAP) Stock Price Down 2.3%
Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) fell 2.3% on Tuesday . The company traded as low as $8.58 and last traded at $8.73, with a volume of 126,964 shares trading hands. The stock had previously closed at $8.94.
A number of brokerages recently weighed in on ADAP. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a research report on Tuesday. Leerink Swann reiterated a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a research report on Sunday, April 24th. Six analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $15.94.
The stock’s 50 day moving average price is $9.38 and its 200-day moving average price is $8.90. The firm’s market cap is $617.25 million.
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.03. Analysts predict that Adaptimmune Therapeutics PLC – will post ($1.12) EPS for the current fiscal year.
In other news, Director Orbimed Advisors Llc purchased 1,712,400 shares of the business’s stock in a transaction dated Tuesday, May 24th. The stock was bought at an average price of $10.42 per share, for a total transaction of $17,843,208.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Charles Elliott Sigal purchased 45,000 shares of the business’s stock in a transaction dated Wednesday, May 18th. The shares were purchased at an average price of $1.53 per share, with a total value of $68,850.00. Following the purchase, the director now directly owns 52,938 shares in the company, valued at approximately $80,995.14. The disclosure for this purchase can be found here.
Several hedge funds and institutional investors have recently bought and sold shares of the company. Marshall Wace LLP purchased a new position in Adaptimmune Therapeutics PLC – during the fourth quarter valued at $1,700,000. Tekla Capital Management LLC increased its position in Adaptimmune Therapeutics PLC – by 5.3% in the fourth quarter. Tekla Capital Management LLC now owns 296,934 shares of the company’s stock valued at $3,581,000 after buying an additional 15,000 shares during the last quarter. Finally, Jennison Associates LLC increased its position in Adaptimmune Therapeutics PLC – by 0.3% in the fourth quarter. Jennison Associates LLC now owns 486,948 shares of the company’s stock valued at $5,873,000 after buying an additional 1,547 shares during the last quarter.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.